Next-Generation Sequencing Workflow for NSCLC Critical Samples Using a Targeted Sequencing Approach by Ion Torrent PGM™ Platform

Next-generation sequencing (NGS) is a cost-effective technology capable of screening several genes simultaneously; however, its application in a clinical context requires an established workflow to acquire reliable sequencing results. Here, we report an optimized NGS workflow analyzing 22 lung cancer-related genes to sequence critical samples such as DNA from formalin-fixed paraffin-embedded (FFPE) blocks and circulating free DNA (cfDNA). Snap frozen and matched FFPE gDNA from 12 non-small cell lung cancer (NSCLC) patients, whose gDNA fragmentation status was previously evaluated using a multiplex PCR-based quality control, were successfully sequenced with Ion Torrent PGM™. The robust bioinformatic pipeline allowed us to correctly call both Single Nucleotide Variants (SNVs) and indels with a detection limit of 5%, achieving 100% specificity and 96% sensitivity. This workflow was also validated in 13 FFPE NSCLC biopsies. Furthermore, a specific protocol for low input gDNA capable of producing good sequencing data with high coverage, high uniformity, and a low error rate was also optimized. In conclusion, we demonstrate the feasibility of obtaining gDNA from FFPE samples suitable for NGS by performing appropriate quality controls. The optimized workflow, capable of screening low input gDNA, highlights NGS as a potential tool in the detection, disease monitoring, and treatment of NSCLC.

[1]  F. Sanger,et al.  DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Vladimir Makarov,et al.  Two methods of whole-genome amplification enable accurate genotyping across a 2320-SNP linkage panel. , 2004, Genome research.

[3]  P. Nederlof,et al.  A multiplex PCR predictor for aCGH success of FFPE samples , 2005, British Journal of Cancer.

[4]  Angela N. Brooks,et al.  Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.

[5]  Rakesh Nagarajan,et al.  Clinical next‐generation sequencing in patients with non–small cell lung cancer , 2015, Cancer.

[6]  C. Cole,et al.  COSMIC (Catalogue of Somatic Mutations in Cancer) , 2014 .

[7]  N. Rothman,et al.  Comparison of yield and genotyping performance of multiple displacement amplification and OmniPlex™ whole genome amplified DNA generated from multiple DNA sources , 2005, Human mutation.

[8]  Ashish Choudhary,et al.  Evaluation of an integrated clinical workflow for targeted next-generation sequencing of low-quality tumor DNA using a 51-gene enrichment panel , 2014, BMC Medical Genomics.

[9]  N. Carter,et al.  Degenerate oligonucleotide-primed PCR: general amplification of target DNA by a single degenerate primer. , 1992, Genomics.

[10]  Joshua L. Deignan,et al.  ACMG clinical laboratory standards for next-generation sequencing , 2013, Genetics in Medicine.

[11]  G. Hampton,et al.  Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing. , 2014, The oncologist.

[12]  A. Oberthuer,et al.  Identification of ALK germline mutation (3605delG) in pediatric anaplastic medulloblastoma , 2012, Journal of Human Genetics.

[13]  N. Girard,et al.  Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002 , 2014, Clinical Cancer Research.

[14]  R. Hubert,et al.  Whole genome amplification from a single cell: implications for genetic analysis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Yu Cao,et al.  Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing , 2014, Science.

[16]  C. Dooms,et al.  Performance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort study , 2014, Translational Respiratory Medicine.

[17]  A. Singh,et al.  Single cell genome sequencing. , 2012, Current opinion in biotechnology.

[18]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[19]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration , 2012, Briefings Bioinform..

[20]  Z. Szallasi,et al.  Spatial and temporal diversity in genomic instability processes defines lung cancer evolution , 2014, Science.

[21]  Pablo Cingolani,et al.  © 2012 Landes Bioscience. Do not distribute. , 2022 .

[22]  T. Beaty,et al.  Comparing whole-genome amplification methods and sources of biological samples for single-nucleotide polymorphism genotyping. , 2005, Clinical chemistry.

[23]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[24]  M. Tsao,et al.  Tissue Heterogeneity of EGFR Mutation in Lung Adenocarcinoma , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[25]  S. Goodman,et al.  Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.

[26]  S. Antonarakis,et al.  Corrigendum: Mutation nomenclature extensions and suggestions to describe complex mutations: A discussion , 2002, Human mutation.

[27]  Sabine Tejpar,et al.  Clinical Validation of Targeted Next Generation Sequencing for Colon and Lung Cancers , 2015, PloS one.

[28]  Xiuqin Jiang,et al.  Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small cell lung cancer , 2014, Cancer biology & therapy.

[29]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[30]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[31]  Mark B Gerstein,et al.  Assessment of whole genome amplification-induced bias through high-throughput, massively parallel whole genome sequencing , 2006, BMC Genomics.

[32]  Adam C. Marko,et al.  Functional DNA quantification guides accurate next-generation sequencing mutation detection in formalin-fixed, paraffin-embedded tumor biopsies , 2013, Genome Medicine.

[33]  A. Ballestrero,et al.  Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition , 2015, Targeted Oncology.

[34]  K. Shadan,et al.  Available online: , 2012 .

[35]  P. Lizardi,et al.  Mutation detection and single-molecule counting using isothermal rolling-circle amplification , 1998, Nature Genetics.

[36]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[37]  Bert Vogelstein,et al.  DETECTION OF CIRCULATING TUMOR DNA IN EARLY AND LATE STAGE HUMAN MALIGNANCIES , 2014 .

[38]  L. Diaz,et al.  Liquid biopsies: genotyping circulating tumor DNA. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Russell Higuchi,et al.  Kinetic PCR Analysis: Real-time Monitoring of DNA Amplification Reactions , 1993, Bio/Technology.

[40]  S. Chanock,et al.  Effects of DNA mass on multiple displacement whole genome amplification and genotyping performance , 2005, BMC biotechnology.

[41]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[42]  J. Todd,et al.  BMC Biotechnology BioMed Central Methodology article A gene expression system offering multiple levels of regulation: the Dual Drug Control (DDC) system , 2004 .

[43]  Ashish Choudhary,et al.  Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. , 2013, The Journal of molecular diagnostics : JMD.

[44]  Li Ding,et al.  Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers , 2012, Cell.

[45]  Stephen J. Chanock,et al.  The new sequencer on the block: comparison of Life Technology’s Proton sequencer to an Illumina HiSeq for whole-exome sequencing , 2013, Human Genetics.

[46]  Wen Tan,et al.  Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer , 2006, Human mutation.

[47]  M. Wrensch,et al.  DNA Quantification of Whole Genome Amplified Samples for Genotyping on a Multiplexed Bead Array Platform , 2007, Cancer Epidemiology Biomarkers & Prevention.

[48]  Vladimir Makarov,et al.  Use of in vitro OmniPlex libraries for high-throughput comparative genomics and molecular haplotyping , 2002, SPIE BiOS.

[49]  F. Boccardo,et al.  Next generation sequencing in non-small cell lung cancer: new avenues toward the personalized medicine. , 2015, Current drug targets.

[50]  A. Wilm,et al.  LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets , 2012, Nucleic acids research.

[51]  Roger S Lasken,et al.  Unbiased whole-genome amplification directly from clinical samples. , 2003, Genome Research.

[52]  H. Koong,et al.  Using Whole Genome Amplification (WGA) of Low-Volume Biopsies to Assess the Prognostic Role of EGFR, KRAS, p53, and CMET Mutations in Advanced-Stage Non-small Cell Lung Cancer (NSCLC) , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[53]  Rita T. Lawlor,et al.  DNA Qualification Workflow for Next Generation Sequencing of Histopathological Samples , 2013, PloS one.

[54]  Rameen Beroukhim,et al.  Genome coverage and sequence fidelity of phi29 polymerase-based multiple strand displacement whole genome amplification. , 2004, Nucleic acids research.

[55]  J. Langmore Rubicon Genomics, Inc. , 2002, Pharmacogenomics.

[56]  S. Kingsmore,et al.  Comprehensive human genome amplification using multiple displacement amplification , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[57]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[58]  J. Ross,et al.  Comprehensive next-generation cancer genome sequencing in the era of targeted therapy and personalized oncology. , 2011, Biomarkers in medicine.

[59]  N. Lennon,et al.  Characterizing and measuring bias in sequence data , 2013, Genome Biology.

[60]  M. Ronaghi,et al.  A Sequencing Method Based on Real-Time Pyrophosphate , 1998, Science.